Received Oct 27, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| UNK | VACCINE NOT SPECIFIED (NO BRAND NAME) | UNKNOWN MANUFACTURER | 1 | — | — |
Intravascular administration of Fluarix instead of the Intramuscular route; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of intramuscular formulation administered by other route in a 62-year-old female patient who received Flu Seasonal TIV Dresden (Fluarix 2025-2026 season) for prophylaxis. On 03-OCT-2025, the patient received the 1st dose of Fluarix 2025-2026 season. On 03-OCT-2025, an unknown time after receiving Fluarix 2025-2026 season, the patient experienced intramuscular formulation administered by other route (Verbatim: Intravascular administration of Fluarix instead of the Intramuscular route). The outcome of the intramuscular formulation administered by other route was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 03-OCT-2025 The nurse reported that the Intravascular administration of Fluarix instead of the Intramuscular route to the patient. She called to know if there were safety concerns to take care of with the patient and to know if a new dose should be administered. The batch number was not provided upon follow up with the reporter.